ArticleBioinformatics advances2026
Integrative multi-omics analysis identifies methylation-associated lncRNAs FAM83A-AS2 and AC012213.1 as candidate prognostic markers in lung adenocarcinoma.
Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: The Motivation: Long non-coding RNAs (lncRNAs) are important regulators of gene expression and are increasingly implicated in cancer. However, the extent to which aberrant DNA methylation is associated with lncRNA dysregulation in lung adenocarcinoma (LUAD) remains underexplored. Results: By integrating RNA-seq and Illumina 450K methylation data from 473 LUAD and 32 normal lung samples in TCGA, we identified 2,668 differentially expressed lncRNAs and 20,843 differentially methylated CpG sites. Mapping CpGs to lncRNA promoters (-1.5 kb from the annotated TSS) and Spearman correlation analysis highlighted seven lncRNAs with inverse promoter methylation-expression patterns; FAM83A-AS2 and AC012213.1 showed the most consistent associations and were linked to poorer overall survival in Kaplan-Meier and Cox models (adjusted for age, sex, and tumor stage). A two-lncRNA prognostic score derived using LASSO Cox regression showed moderate time-dependent discrimination at 590 days (AUC = 0.72) within the TCGA cohort. An exploratory lncRNA-miRNA-mRNA network suggested miRNA-mediated regulation of LUAD genes, with enrichment analyses linking targets to chromatin modification and epigenetic regulation. These findings nominate FAM83A-AS2 and AC012213.1 as candidate epigenetically associated prognostic lncRNAs in LUAD, warranting validation in independent cohorts and functional studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.